Literature DB >> 2830843

Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.

G S Kobayashi1, S J Travis, G Medoff.   

Abstract

Fluconazole (UK-49,858) was compared with amphotericin B in treating histoplasmosis in female AKR mice immunosuppressed with either cyclophosphamide or cortisone. Both drugs protected animals from a lethal challenge with Histoplasma capsulatum, but neither regimen resulted in cures since viable organisms were cultured from spleens of survivors.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2830843      PMCID： PMC175844          DOI： 10.1128/AAC.31.12.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Medical mycology in crisis.

Authors:  W E Bullock; G S Deepe
Journal:  J Lab Clin Med       Date:  1983-11

3.  In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester.

Authors:  G S Kobayashi; J R Little; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

4.  Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.

Authors:  T E Rogers; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S Travis; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

6.  Treatment of cryptococcal meningitis in mice with fluconazole.

Authors:  E Palou de Fernandez; M M Patino; J R Graybill; M H Tarbit
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

7.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

8.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

9.  Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

10.  Candida infections in surgical patients.

Authors:  P K Marsh; F P Tally; J Kellum; A Callow; S L Gorbach
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969
View more
  11 in total

Review 1.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 4.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 5.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

6.  Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis.

Authors:  D Pappagianis; B L Zimmer; G Theodoropoulos; M Plempel; R F Hector
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

8.  Amphotericin B lipid complex therapy of experimental fungal infections in mice.

Authors:  J M Clark; R R Whitney; S J Olsen; R J George; M R Swerdel; L Kunselman; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 9.  New antifungal agents for the systemic mycoses.

Authors:  S M Ringel
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

10.  Treatment of histoplasmosis with MK-991 (L-743,872).

Authors:  J R Graybill; L K Najvar; E M Montalbo; F J Barchiesi; M F Luther; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.